New research from Bausch + Lomb has found that dry eye disease remains one of the least recognised conditions affecting women during and after menopause. The survey highlights a significant gap in
MoreAstraZeneca (AZN) appears to be stepping back from combination therapy approaches in transthyretin amyloid cardiomyopathy following a significant phase 3 clinical failure. The setback involved Wainua, a drug developed in partnership with
MoreMeeting the legal requirements of DSCSA and building genuine operational efficiency are two very different things, according to a senior industry figure. Gregg Gorniak, vice president of manufacturer operations and data services
MoreNovartis has announced positive topline results from its Phase 3 REMODEL-1 and REMODEL-2 trials of remibrutinib in relapsing multiple sclerosis. Remibrutinib is a highly selective and potent oral Bruton’s tyrosine kinase inhibitor
MoreThe pharmaceutical industry faces mounting pressure as blockbuster drug patents expire, opening markets to both generic and biosimilar competitors across the globe. Patent cliffs represent moments when brand-name drug manufacturers lose exclusivity,
MoreEmergent BioSolutions (NYSE: EBS) is ramping up its opioid overdose education efforts across North America in recognition of International Overdose Awareness Day. The company is targeting college campuses across the United States
MoreThe FDA is pressing ahead with national licensure standards for wholesale distributors and third-party logistics providers, raising urgent questions across the pharmaceutical supply chain. At the heart of the debate is whether
MoreThe White House has announced a second wave of most favoured nation drug pricing agreements, this time targeting nine medium-sized pharmaceutical companies across multiple continents. The latest round includes Alcon, Astellas Pharma,
MoreThe Trump administration has added nine pharmaceutical companies to its Most-Favored-Nation pricing program, bringing the total number of participating drugmakers to 26. President Donald J. Trump announced the expansion on August 31,
MoreLonza, widely regarded as the world’s leading contract development and manufacturing organisation, has named Samanta Cimitan as its new Chief Commercial Officer, Senior Vice President and Member of the Extended Executive Committee.
More
